You seem to be asking a rhetorical question but I can't help myself.....
I wonder why the trial has been put in with coronary revascularisation trials?
From http://www.mesoblast.com/science/mechanisms-of-action
MPC-150-IM is designed for local delivery to damaged heart muscle and to allow the MLCs to secrete biomolecules involved in myocardial neovascularization, cardiomyocyte survival, cardiomyocyte precursor migration and proliferation, and reduction in fibrosis and myocardial scarring. Biomolecules include stromal cell-derived factor 1, Angiopoietin-1, vascular endothelial growth factor (VEGF), hepatocyte growth factor, and matrix metalloproteinases.
Bold my emphasis
If you want to revascularise why not get the heart to do it with a little help.
- And then last is the results of the MSB trial.
I guess they were keeping the best till last
Ann: End-Stage HF Results Selected For AHA Scientific Sessions, page-49
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
0.015(1.53%) |
Mkt cap ! $1.167B | |||
| Open | High | Low | Value | Volume |
| $1.01 | $1.04 | 99.0¢ | $3.204M | 3.157M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 62435 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 91708 | 38 |
View Market Depth
| Last trade - 13.37pm 16/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |